Danaher (DHR) has expressed takeover interest in contract manufacturer Catalent (CTLT) and overtures made in recent months valued Catalent at "a significant premium," people familiar with the matter told Bloomberg’s Liana Baker, Michelle Davis and Ed Hammond. Sources said it is unclear how Catalent will proceed or whether it’s receptive to an offer, adding that a deal is not imminent, according to the report. A representative for Danaher didn’t immediately respond to a request for comment, while a representative for Catalent said in an emailed statement that "as a matter of company policy, Catalent does not comment on market rumors or speculation," the report noted. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CTLT:
- Catalent price target lowered to $58 from $62 at Barclays
- Catalent appoints Zayas as SVP, Operations, Biologics North America
- Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports
- Early notable gainers among liquid option names on January 11th
- Avantor, Catalent enter multi-year supply agreement